BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

Leaders of some of the world’s leading biopharma companies faced off last week against congressional Democrats – and were soundly defeated. The two-day hearing on drug pricing convened by the House Oversight...
BioCentury | Oct 1, 2020
Politics, Policy & Law

House committee targets Mallinckrodt, Amgen and Novartis over price increases

During the second and final day of a drug pricing hearing, Democratic members of the House Oversight and Reform Committee again pounded pharma CEOs, accusing them of taking unjustified price increases...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jul 18, 2020
Finance

Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C

...Phase Ib wrapped up in May, and Imvax aims to publish the final data soon. HP...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

...COVID-19 pandemic.” The PHALCON-EE trial is testing vonoprazan in patients with erosive esophagitis, and the PHALCON-HP...
BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...Athena’s case, along with two other cases, Hikma Pharmaceuticals, et al. v. Vanda Pharmaceuticals and HP...
BioCentury | Dec 20, 2019
Targets & Mechanisms

Controlling T cells via epigenetics

An international academic team has discovered an epigenetic pathway that regulates CD4 + T cell differentiation and activity, and could yield new therapeutic targets for autoimmunity. As drug developers seek the next generation of targeted...
BioCentury | Oct 22, 2019
Politics & Policy

Trump re-launches science advisory committee

...of Dow Chemical Co.; Shane Wall, CTO of HP Inc. (NYSE:HPQ) and global head of HP...
BioCentury | Dec 7, 2018
Clinical News

RedHill planning NDA for H. pylori antibiotic following second Phase III readout

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said on Dec. 3 that it plans to submit an NDA to FDA next half for Talicia (RHB-105) as first-line treatment of Helicobacter pylori infection regardless of ulcer status...
BioCentury | Dec 3, 2018
Clinical News

RedHill planning NDA for H. pylori antibiotic following second Phase III readout

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) plans to submit an NDA to FDA next half for Talicia (RHB-105) as first-line treatment of Helicobacter pylori infection regardless of ulcer status after reporting that the antibiotic met...
Items per page:
1 - 10 of 218